Page last updated: 2024-09-05

enzastaurin and Cancer of Prostate

enzastaurin has been researched along with Cancer of Prostate in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dreicer, R; Garcia, J; Hussain, M; Kania, M; Raghavan, D; Rini, B; Somer, B; Srinivas, S; Vogelzang, N; Zhao, YD	1
Bailey, SN; Banks, C; Brown, TJ; Campbell, RM; Capen, A; Geeganage, S; Goode, R; Graff, JR; Hanna, KR; Huss, KL; Iversen, PW; Konicek, BW; Lewis, JE; Lynch, RL; McNulty, AM; Musib, L; Neubauer, BL; Sams, L; Thornton, D	1

Trials

1 trial(s) available for enzastaurin and Cancer of Prostate

Article	Year
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Investigational new drugs, 2011, Volume: 29, Issue:6 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease-Free Survival; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome	2011

Article

Year

Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease.

Investigational new drugs, 2011, Volume: 29, Issue:6

Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease-Free Survival; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome

2011

Other Studies

1 other study(ies) available for enzastaurin and Cancer of Prostate

Article	Year
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer research, 2005, Aug-15, Volume: 65, Issue:16 Topics: Animals; Apoptosis; Cell Growth Processes; Colonic Neoplasms; Female; Glioblastoma; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HCT116 Cells; Humans; Indoles; Male; Mice; Mice, Nude; Phosphorylation; Prostatic Neoplasms; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6; Signal Transduction; Xenograft Model Antitumor Assays	2005

Article

Year

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.

Cancer research, 2005, Aug-15, Volume: 65, Issue:16

Topics: Animals; Apoptosis; Cell Growth Processes; Colonic Neoplasms; Female; Glioblastoma; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HCT116 Cells; Humans; Indoles; Male; Mice; Mice, Nude; Phosphorylation; Prostatic Neoplasms; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6; Signal Transduction; Xenograft Model Antitumor Assays

2005